Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now
TSX Penny Stock Picks For January 2025

In This Article:

As we step into 2025, the Canadian market is navigating a landscape shaped by new U.S. policies on energy, immigration, tariffs, and technology. With the TSX index showing resilience since Inauguration Day and potential rate adjustments by the Bank of Canada on the horizon, investors are keenly observing these developments. Amidst this backdrop, penny stocks—often representing smaller or emerging companies—remain a niche yet intriguing investment area for those seeking growth opportunities backed by solid financial foundations.

Top 10 Penny Stocks In Canada

Name

Share Price

Market Cap

Financial Health Rating

Silvercorp Metals (TSX:SVM)

CA$4.29

CA$965.98M

★★★★★★

Mandalay Resources (TSX:MND)

CA$4.33

CA$432.92M

★★★★★★

Pulse Seismic (TSX:PSD)

CA$2.42

CA$124.04M

★★★★★★

Foraco International (TSX:FAR)

CA$2.26

CA$231.32M

★★★★★☆

Findev (TSXV:FDI)

CA$0.495

CA$13.75M

★★★★★★

PetroTal (TSX:TAL)

CA$0.68

CA$632.62M

★★★★★★

NamSys (TSXV:CTZ)

CA$1.00

CA$26.86M

★★★★★★

East West Petroleum (TSXV:EW)

CA$0.04

CA$4.07M

★★★★★★

Hemisphere Energy (TSXV:HME)

CA$1.83

CA$179.61M

★★★★★☆

DIRTT Environmental Solutions (TSX:DRT)

CA$1.16

CA$228.22M

★★★★☆☆

Click here to see the full list of 936 stocks from our TSX Penny Stocks screener.

Let's dive into some prime choices out of the screener.

InnoCan Pharma

Simply Wall St Financial Health Rating: ★★★★★★

Overview: InnoCan Pharma Corporation is a pharmaceutical technology company that develops drug delivery platforms combining cannabidiol (CBD) with other pharmaceutical ingredients across the United States, Canada, Europe, and internationally, with a market cap of CA$49.32 million.

Operations: The company generates revenue primarily through online sales amounting to $28.86 million, with minimal contributions from other operations totaling $0.07 million.

Market Cap: CA$49.32M

InnoCan Pharma, with a market cap of CA$49.32 million, is navigating the penny stock landscape by focusing on innovative CBD drug delivery platforms. Despite being unprofitable, it has reduced losses by 10.5% annually over five years and remains debt-free. The company has a cash runway for 1.5 years if current free cash flow trends persist and has not diluted shareholders recently. Recent private placements raised CAD 635,444.60 to support operations, while promising safety results from its LPT-CBD product in minipigs suggest potential in chronic pain treatment markets.